Dr. Michael Berquist’s research goal is to prevent the development of alcohol use disorder in individuals with stress exposure, including exposure to early life adversity and prenatal opioid exposure. Our group is currently interested in the use of psychedelics, including novel lysergamides, to thwart alcohol drinking and preference. Dr. Berquist primarily uses behavioral assays in rodents and collaborates with UAMS faculty to study the impact of stress exposure on alcohol use, as well as to test putative medications for alcohol use disorder. Dr. Berquist also is developing a new project centered on medications used to treat migraine-associated pain and cognitive disruption.